Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

About jeremiah@devisedesigns.com

This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 151 entries already.

Entries by jeremiah@devisedesigns.com

Oncology

Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.

Ligr et al. • 2012 • J Urol. 2012;188(3):981-8.

September 18, 2018
Oncology

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Tieszen et al. • 2011 • BMC Cancer. 2011;11:207.

September 18, 2018
Oncology

Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.

Yan et al. • 2008 • Urol Int. 2008;81(2):228-33.

September 18, 2018
Oncology

Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro.

Zhang et al. • 2008 • Zhonghua Wai Ke Za Zhi. 2006;44(6):382-5.

September 18, 2018
Oncology

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

Nanda et al. • 2016 • Springerplus. 2016;5(1):947.

September 18, 2018
Oncology

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Baker et al. • 2015 • Cancer Manag Res. 2015;7:361-8.

September 18, 2018
Oncology

A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

Nanda et al. • 2013 • Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-21.

September 18, 2018
Other

Glucocorticoid receptors in the prefrontal cortex regulate dopamine efflux to stress via descending glutamatergic feedback to the ventral tegmental area.

Butts KA, Phillips AG. • 2013 • Int J Neuropsychopharmacol. 2013;16(8):1799-807.

September 18, 2018
Other

A mixed glucocorticoid/mineralocorticoid receptor modulator dampens endocrine and hippocampal stress responsivity in male rats.

Nguyen et al. • 2017 • Physiol Behav. 2017;178:82-92.

September 18, 2018
Other

The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.

Solomon et al. • 2014 • Horm Behav. 2014;65(4):363-71.

September 18, 2018
Page 12 of 16«‹1011121314›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top